NASDAQ$PRME
Prime Medicine Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Prime Medicine Inc reported a net loss of $52.6 million for the three months ended June 30, 2025.
The company recorded collaboration revenue of $1.1 million from its related party agreement. Operating expenses totaled $54.5 million, primarily driven by research and development activities of $41.4 million. Cash and cash equivalents stood at $53.8 million at quarter end, with total assets of $279.0 million.
- Collaboration revenue from related party reached $1.1 million in Q2 2025.
- Net loss narrowed slightly to $52.6 million compared to $55.3 million in the prior year quarter.
- R&D expenses decreased to $41.4 million from $43.1 million year-over-year.
- Cash position of $53.8 million supports operations into 2027 following subsequent financing.
Headline financials
Revenue & EPS history
Prime Medicine · Revenue · Quarterly
$1.12M
Revenue by segment
Prime Medicine · $1.12M total across 1 segment · Q2 2025
- Collaboration revenue — related party$1.12M—100.0%
Forward guidance
Company plans to focus resources on in vivo liver franchise with IND filings targeted for first half and mid-2026; cash runway extended into 2027 with recent financing.
Tailwinds
- Cash runway into 2027 supported by August 2025 offering of $138.2 million net proceeds.
- Progress on Wilson's Disease and AATD programs in late preclinical stage.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports
-1.7%
Avg return
Earnings day
-7.2%
Avg return
5 days after
-10.8%
Avg return
30 days after
29%
5 / 17 earnings
Positive
+26.6%
Q1 2025
Best reaction
-9.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q4 2025 | -8.2% | -13.9% | -28.8% | |
| Q3 2025 | -9.1% | -15.1% | -10.5% | |
| Q1 2025 | +26.6% | -7.5% | +15.9% | |
| Q4 2024 | +4.1% | -4.5% | -17.8% | |
| Q3 2024 | -9.8% | -23.8% | -31.4% | |
| Q2 2024 | -4.5% | -2.5% | -19.3% | |
| Q1 2024 | +12.2% | +18.2% | +14.9% | |
| Q4 2023 | +1.6% | -2.4% | -18.9% | |
| Q3 2023 | +17.0% | +13.1% | +21.6% | |
| Q2 2023 | -7.5% | -14.9% | -13.3% | |
| Q1 2022 | -9.4% | -10.5% | +3.2% | |
| Q1 2023 | -9.4% | -10.5% | +3.2% | |
| Q4 2020 | -9.7% | -11.7% | -21.9% | |
| Q4 2022 | -9.7% | -11.7% | -21.9% | |
| Q3 2022 | -4.4% | -8.1% | -19.4% | |
| Q3 2021 | -4.4% | -8.1% | -19.4% | |
| Q4 2021 | -4.4% | -8.1% | -19.4% | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro